Current Report Filing (8-k)
September 21 2020 - 6:11AM
Edgar (US Regulatory)
0001579428
false
0001579428
2020-09-21
2020-09-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
September 21, 2020
Date of report (Date of earliest event reported)
Axsome Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37635
|
|
45-4241907
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
22 Cortlandt Street, 16th Floor
New York, New York
(Address of principal executive offices)
|
|
10007
(Zip Code)
|
Registrant’s telephone number, including
area code (212) 332-3241
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock, Par Value $0.0001 Per Share
|
|
AXSM
|
|
The Nasdaq Global Market
|
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On September 21, 2020, Axsome Therapeutics,
Inc. issued a press release confirming the expedited development of AXS-12 for the treatment of narcolepsy following a Breakthrough
Therapy meeting with the U.S. Food and Drug Administration.
The full text of the press release is filed
as Exhibit 99.1 hereto, and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Axsome Therapeutics, Inc.
|
|
|
Dated: September 21, 2020
|
By:
|
/s/
Herriot Tabuteau, M.D.
|
|
Name:
|
Herriot Tabuteau, M.D.
|
|
Title:
|
President and Chief Executive Officer
|
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2024 to May 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2023 to May 2024